Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lanifibranor - Inventiva Pharma

Drug Profile

Lanifibranor - Inventiva Pharma

Alternative Names: IVA-337

Latest Information Update: 02 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inventiva Pharma
  • Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Antineoplastics; Hepatoprotectants; Skin disorder therapies; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
  • No development reported Bladder cancer; Fibrosis
  • Discontinued Systemic scleroderma

Most Recent Events

  • 28 Nov 2019 No recent reports of development identified for preclinical development in Bladder-cancer in France (PO)
  • 26 Sep 2019 Lanifibranor - Inventiva Pharma receives Fast Track designation for Non-alcoholic steatohepatitis [PO,Tablet] in USA
  • 26 Sep 2019 Inventiva Pharma plans a pivotal phase III trial in Non-alcoholic steatohepatitis after positive outcomes from the phase IIb trial
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top